Skip to main navigation Skip to search Skip to main content

VX18-445-113: A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-4445 Combination Therapy in Subjects with Cystic Fibrosis

Project: Research

Project Details

StatusActive
Effective start/end date09/6/19 → 12/31/26

Funding

  • Vertex Pharmaceuticals Incorporated: $254,781.62